Future trends in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection: An in-depth review of newer antibiotics active against an enduring pathogen

被引：52
作者：
Bal, A. M. [1 ]
David, M. Z. [2 ,3 ,4 ]
Garau, J. [5 ]
Gottlieb, T. [6 ]
Mazzei, T. [7 ]
Scaglione, F. [8 ]
Tattevin, P. [9 ]
Gould, I. M. [10 ]
机构：
[1] Univ Hosp Crosshouse, Dept Microbiol, Kilmarnock KA2 0BE, Scotland
[2] Univ Chicago, Dept Med, Chicago, IL 60637 USA
[3] Univ Chicago, Dept Paediat, Chicago, IL 60637 USA
[4] Univ Chicago, Dept Publ Hlth Sci, Chicago, IL 60637 USA
[5] Univ Mutua Terrassa, Dept Med, Plaza Dr Robert 5, Barcelona 08221, Spain
[6] Concord Hosp, Dept Microbiol & Infect Dis, Sydney, NSW 2139, Australia
[7] Univ Firenze, Dept Hlth Sci, Clin Pharmacol & Oncol Sect, Florence, Italy
[8] Univ Milan, Dept Oncol & Oncohaematol, Via Vanvitelli 32, I-20129 Milan, Italy
[9] Pontchaillou Univ Hosp, Infect Dis & Intens Care Unit, F-35033 Rennes, France
[10] Aberdeen Royal Infirm, Dept Microbiol, Aberdeen AB25 2ZN, Scotland
来源：
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE | 2017年 / 10卷
关键词：
MRSA infection; Combination antibiotics; New antibiotics; ACUTE BACTERIAL SKIN; SINGLE-DOSE ORITAVANCIN; BETA-LACTAMS; DOUBLE-BLIND; CEFTOBIPROLE MEDOCARIL; COMPLICATED SKIN; ANTIBACTERIAL ACTIVITY; TEDIZOLID PHOSPHATE; COMBINATION THERAPY; CONFERS RESISTANCE;
D O I：
10.1016/j.jgar.2017.05.019
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
Methicillin-resistant Staphylococcus aureus (MRSA) continues to be a major public health problem. Vancomycin and teicoplanin have been in clinical use for several decades but their drawbacks are well described. In the last 10 years, several antibiotics have been made available for clinical use. Daptomycin and linezolid have been extensively used during this period. Other agents such as ceftaroline, ceftobiprole, dalbavancin, oritavancin, tedizolid and telavancin have been approved by regulatory agencies since 2009. Many others, such as the newer tetracyclines, fluoroquinolones, oxazolidinones and pleuromutilins, are in various stages of development. In addition, an ongoing multicentre trial is investigating the role of combination of vancomycin or daptomycin with beta-lactam antibiotics. This review discusses the role of the newer antibiotics, reflecting the views of the 6th MRSA Consensus Conference meeting of the International Society of Chemotherapy MRSA Working Group that took place in 2016. (C) 2017 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码：295 / 303
页数：9
相关论文
共 95 条
  • [1] Reduced In Vitro Activity of Ceftaroline by Etest among Clonal Complex 239 Methicillin-Resistant Staphylococcus aureus Clinical Strains from Australia
    Abbott, I. J.
    Jenney, A. W. J.
    Jeremiah, C. J.
    Mirceta, M.
    Kandiah, J. P.
    Holt, D. C.
    Tong, S. Y. C.
    Spelman, D. W.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (12) : 7837 - 7841
  • [2] Factors influencing the clinical outcome of methicillin-resistant Staphylococcus aureus bacteraemia
    Albur, M. S.
    Bowker, K.
    Weir, I.
    MacGowan, A.
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2012, 31 (03) : 295 - 301
  • [3] [Anonymous], PLOS ONE
  • [4] Antony Suresh J., 2017, Infectious Disorders - Drug Targets, V17, P77, DOI 10.2174/1871526517666161108130148
  • [5] A Phase 3 Randomized Double-Blind Comparison of Ceftobiprole Medocaril Versus Ceftazidime Plus Linezolid for the Treatment of Hospital-Acquired Pneumonia
    Awad, Samir S.
    Rodriguez, Alejandro H.
    Chuang, Yin-Ching
    Marjanek, Zsuszanna
    Pareigis, Alex J.
    Reis, Gilmar
    Scheeren, Thomas W. L.
    Sanchez, Alejandro S.
    Zhou, Xin
    Saulay, Mikal
    Engelhardt, Marc
    [J]. CLINICAL INFECTIOUS DISEASES, 2014, 59 (01) : 51 - 61
  • [6] Vancomycin in the treatment of meticillin-resistant Staphylococcus aureus (MRSA) infection: End of an era?
    Bal, A. M.
    Garau, J.
    Gould, I. M.
    Liao, C. H.
    Mazzei, T.
    Ninnno, G. R.
    Soriano, A.
    Stefani, S.
    Tenover, F. C.
    [J]. JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2013, 1 (01) : 23 - 30
  • [7] Potent synergy of ceftobiprole plus daptomycin against multiple strains of Staphylococcus aureus with various resistance phenotypes
    Barber, Katie E.
    Werth, Brian J.
    Ireland, Cortney E.
    Stone, Nicole E.
    Nonejuie, Poochit
    Sakoulas, George
    Pogliano, Joseph
    Rybak, Michael J.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (11) : 3006 - 3010
  • [8] Daptomycin non-susceptible, vancomycin-intermediate Staphylococcus aureus endocarditis treated with ceftaroline and daptomycin: case report and brief review of the literature
    Baxi, Sanjiv M.
    Chan, Dominic
    Jain, Vivek
    [J]. INFECTION, 2015, 43 (06) : 751 - 754
  • [9] Penicillin Binding Protein 1 Is Important in the Compensatory Response of Staphylococcus aureus to Daptomycin-Induced Membrane Damage and Is a Potential Target for β-Lactam-Daptomycin Synergy
    Berti, Andrew D.
    Theisen, Erin
    Sauer, John-Demian
    Nonejuie, Poochit
    Olson, Joshua
    Pogliano, Joseph
    Sakoulas, George
    Nizet, Victor
    Proctor, Richard A.
    Rose, Warren E.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (01) : 451 - 458
  • [10] Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin Infection
    Boucher, Helen W.
    Wilcox, Mark
    Talbot, George H.
    Puttagunta, Sailaja
    Das, Anita F.
    Dunne, Michael W.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (23) : 2169 - 2179
12345678910